Show simple item record

dc.contributor.authorKelly, K.en
dc.contributor.authorBloor, Adrianen
dc.contributor.authorPatel, A.en
dc.contributor.authorGriffin, J. E.en
dc.contributor.authorRadia, R.en
dc.contributor.authorYeung, D. T.en
dc.contributor.authorSlukvin, I.en
dc.contributor.authorRasko, J.en
dc.date.accessioned2023-10-25T08:48:31Z
dc.date.available2023-10-25T08:48:31Z
dc.date.issued2023en
dc.identifier.citationKelly K, Bloor A, Patel A, Griffin JE, Radia R, Yeung DT, et al. A Phase I Clinical Trial of Ipsc-Derived Mscs (Cyp-001) in Steroid-Resistant Acute Gvhd: Two Year Follow-up Results. Cytotherapy. 2023 Jun;25(6):S12-S. PubMed PMID: WOS:001041036100038.en
dc.identifier.urihttp://hdl.handle.net/10541/626630
dc.language.isoenen
dc.titleA phase I clinical trial of Ipsc-derived Mscs (Cyp-001) in steroid-resistant acute Gvhd: two year follow-up resultsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentCynata Therapeutics Limited, Melbourne, VIC, Australiaen
dc.identifier.journalCytotherapyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record